Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | FCER2 | P06734 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567591 | 0.81 | CNR1 (0.33) | CNR1CNR2CTSDGCKCTSS | |
| SCHEMBL973034 | 0.76 | REN (0.33) | CNR1CNR2GCKCTSSUSP30 | |
| SCHEMBL2024918 | 0.73 | GAA (0.41) | — | |
| SCHEMBL4596150 | 0.71 | AAK1 (0.30) | — | |
| SCHEMBL14321919 | 0.68 | CTSD (0.39) | CNR1CNR2CTSDGCK | |
| SCHEMBL4972360 | 0.67 | CNR2 (0.32) | CNR2CTSDGCKCTSS | |
| SCHEMBL2023386 | 0.67 | CTSS (0.32) | CTSS | |
| SCHEMBL2023551 | 0.67 | CTSS (0.32) | CTSS | |
| SCHEMBL2028712 | 0.67 | CTSS (0.32) | CTSS | |
| SCHEMBL2024328 | 0.67 | CTSS (0.32) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | CNR1 4564/4885CNR2 4689/4885CTSD 75/4885 |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | CNR1 3125/4885CNR2 4139/4885CTSD 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.